Abstract: The invention relates to a treatment for equine viral infections which includes potassium iodide, ammonium chloride and caffeine. A method of treating equine viral infections is also provided which involves administering the composition daily.

Abstract: The antibacterial substance baquiloprim (2,4-diamino-5-[8-dimethylamino-7-methyl-5-quinolylmethyl]pyrimidine) is shown to be active against protozoal infections, e.g. toxoplasmosis. Preferably the baquiloprim is administered together with a sulphonamide.

Abstract: The present invention relates to methods and corresponding agents for lowering plasma Lp(a) levels by the administration of agents that reduce Lp(a) and selectively separate therefrom the apo(a) component and/or prevent Lp(a) formation. Suitable agents include sulfhydryl reducers, such as N-acetylcysteine. The present method and agents may be administered alone or in conjunction with other therapy for the lowering of LDL cholesterol.

Abstract: An oxygen scavenging composition for use with foods, cosmetics, and pharmaceuticals comprising a combination of a metal that can exist in two redox states at ambient conditions, and a radical oxygen scavenger. The oxygen scavenging system is also effective in inhibiting the growth of yeasts, molds, and most aerobic bacteria.

Abstract: The invention relates to a method of improving the growth and the feed efficiency and of increasing the muscle/fat ratio of agricultural domestic animals, in particular bovine animals and sheep, by administering to the animals a composition which comprises as an active substance a compound of the general formula ##STR1## wherein: R.sub.1 is a phenylalkyl group the alkyl group of which comprises 1-3 carbon atoms and the phenyl group of which may be substituted with one or more substituents selected from the group consisting of hydroxy, methoxy, fluoro and methylsulphonylamino, or whereinR.sub.1 is a thienyl alkyl group or a tetrahydrofurylalkyl group the alkyl group of which comprises 1-3 carbon atoms; or whereinR.sub.1 is an optionally branched alkyl group having 1-8 carbon atoms which optionally is substituted with a C.sub.1 -C.sub.4 alkoxy group, a hydroxy group, a C.sub.1 -C.sub.4 alkoxycarbonyl group or a carboxy group; and whereinR.sub.2 and R.sub.

Abstract: A method of stabilizing an aqueous microemulsion of a water-insoluble agriculturally active compound to remain clear and free of precipitation after standing for 6 months at a temperature of 2.degree.-3.degree. C. which comprises adding a polyhydric alcohol with at least 3 hydroxyl groups to the microemulsion.

Abstract: This invention relates to a novel prophylactic/therapeutic agent for the treatment of swine pleuropneumonia which comprises a bicozamycin ester represented by the following formula ##STR1## wherein R means a benzoyl group or a cyclohexanecarbonyl group.

Abstract: A series of cytotropic heterogeneous molecular lipids (CHML) and the method of preparation thereof are disclosed in the invention. CHML provided by this invention is in molecular type, it is an activated molecular carrier of functions with orientionally penetrating into membranes or walls of the cells. It possesses the active site for binding anti-carcinogenic drugs which is water soluble, lipid soluble or gas soluble and possesses the activated portion for binding structure of membrane of cancer cells also.CHML can synergetically injure the carcinoma cells and varius verus, at the same time it can enhance the immunity of the body. These are ascertained by the animal tests and in vitro tests.CHML in this invention can kill the sarcoma cell S-180 within 50 min. and the cells of human squamous cell carcinoma of esophagus within 40 min.The rate of DNA and RNA depolymerizations in cancer cells and mortality of cancer cells are attained to 100%. These are evidenced in the vitro test also.

Abstract: The present invention provides a method of inhibiting gastric acid secretion in mammals by administering a 5-HT1A agonist compound or a pharmaceutically acceptable salt thereof.

Abstract: Compositions comprising a mixture of the antibiotic frenolicin B with a potentiated sulfonamide anticoccidial agent, useful for the treatment and prevention of coccidiosis in animals and methods of treating coccidiosis are disclosed.

Abstract: A method for decreasing the adrenal secretion of glucocorticoids, especially cortisol, in male livestock without substantially suppressing the animal's immune system by oral or other administration of effective doses of melengesterol acetate (MGA) or derivatives thereof. Ideally, the MGA may be used in admixture with the subject animal feed, although it is understood that the compound may be administered separately.

Abstract: An emulsifiable concentrate comprising an agriculturally active chemical, a surfactant, an organic diluent and a solvent having first and second components, the first component being capable of solubilizing the agriculturally active chemical and the second component in conjunction with the surfactant being effective to disperse the agriculturally active chemical. The inventive concentrate allows for high concentrations of the active ingredient, exhibits excellent stability and produces highly stable compositions upon dilution with water.

Abstract: A method of using an imidazoline compound, which is a vasodilator and an alpha-adrenergic blocking agent, for the treatment of symptoms of chronic obstructive pulmonary diseases (COPD), including cystic fibrosis, chronic bronchitis and emphysema, or COPD where it is associated with asthma, comprises administering the imidazoline to a patient by inhalation. Preferably, the imidazoline compound employed is tolazoline. The presentation of an imidazoline compound in a device for the administration of an aerosol is disclosed.

Abstract: A method of preventing or alleviating a migraine headache which comprises administering a pharmaceutically effective amount of a mast cell degranulation blocking agent just prior to or during the prodromal phase of the migraine in the absence of an analgesic. The agent can also be administered in combination with a central nervous system stimulant.

Abstract: This invention relates to a pharmaceutical composition for treating gastrointestinal distress comprising an effective amount of an antidiarrheal composition, e.g. loperamide, and an antiflatulent effective amount of simethicone and methods of treating gastrointestinal distress comprising administering such pharmaceutical compositions.

Abstract: This invention provides a novel class of vitamin D-related compounds, namely the 1.alpha.-hydroxy-19-nor-vitamin D analogs, as well as a general method for their chemical synthesis. The compounds exhibit pronounced activity in arresting the proliferation of undifferentiated cells, including malignant cells, and in inducing their differentiation, and thus represent novel therapeutic agents for the treatment of malignant and other diseases characterized by the proliferative growth of undifferentiated cells. Formulations for therapeutic use and treatment methods are also provided.

Abstract: This invention relates to a method for treating classical migraine headaches. Pursuant to this method, a therapeutic amount of .beta.-adrenergic-blocking agent is administered to a person suffering a migraine attack promptly upon onset of aura. The invention further relates to a method wherein the blocking agent is nasally administered.

Abstract: The composition includes dl-tetrahydropalmatine mixed with its carrier having pharmaceutical therapeutical effect for treating hyperthyroidism. The dl-tetrahydropalmatine may be purified from a chloroform layer extracted from a Corydalis tuber.

Abstract: The present invention relates to biologically-active copolymers and to compounds that can be safely used to cause the thymus of an animal or human to increase in size, thereby replenishing the T-lymphocyte population. When injected into an animal or human with an antigen, certain of the biologically-active copolymers cause immunosuppression to the antigen.When injected into poultry, certain of the biologically-active copolymers modulate immune responsiveness. The biologically active copolymers are also useful as growth promoters for animals. Compounds within the biologically-active copolymers of the present invention are effective tumoricidal agents. At low concentration, certain of the biologically-active copolymers can cause dedifferentiated cells to differentiate.The biologically-active copolymer of the present invention is a safe and non-toxic formulation that can effectively be administered to animals or humans.

Abstract: Unflavored psyllium husk-containing drink mix compositions are prepared consisting essentially of small particle size psyllium husk comprising less than about 10% of psyllium husk having particle sizes larger than about 60 mesh screen, less than about 2.0% edible acid, and sugar. Such compositions are unflavored so as to permit mixing small particle size psyllium, which is readily suspended in a liquid without a gritty texture, with a broader selection of liquids, such as milk and fruit drinks, without rapid gelling of the psyllium husk.